Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DNAG WWWWWWWWWWWWWWWWWWWWWWWEEEEEEEEEEEEEEEEEEEEEE
DNAG WWWWWEEEEEEEEEEEE FLLLLLLLLYYYYYYYYYYYYYYYYYYY
DNAG RRUUUUNNNNNNNNNNNNNIIINNNNNNNGGGGGGGGG
DNAG its running
DNAPrint Announces German Business Partner's Progress in European Clinical Trial for BF-200
SARASOTA, FL and LEVERKUSEN, GERMANY, Dec 27, 2006 (MARKET WIRE via COMTEX) -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its German business partner, Biofrontera AG (FRANKFURT: B8F), in which the Company owns an approximate 10% stake, has completed the enrollment of patients in the first part of its phase IIb/III clinical trial for its lead product, BF-200 ALA, a proposed treatment of actinic keratosis (precancerous and cancerous skin lesions).
Initially, clinical results for three different doses of the active ingredient 5-aminolevulinic acid (ALA) and placebo are compared. Following the treatment and 2-month observation of 80 patients enrolled in the first part of the study, independent experts will perform an interim analysis to select the optimal dose of the drug. All 80 patients have already completed the treatment and Biofrontera expects the results of the interim analysis in the first quarter 2007. Subsequently, efficacy and safety of BF-200 ALA will be verified with an additional 160 patients.
The randomized, placebo-controlled clinical phase IIb/III trial is conducted in 13 centers in Germany. In parallel to the ongoing trial, a second phase III trial is currently prepared with approximately 200 patients to compare BF-200 ALA with a standard therapy. Clinical efficacy of combinations of ALA with nanoemulsions has already been demonstrated for superficial basal cell carcinoma in two earlier phase II trials, where a single treatment eliminated more than 80% of the tumors.
BF-200 ALA
Biofrontera's lead product BF-200 ALA combines a nanoemulsion with 5-aminolevulinic acid (ALA). The product is developed for the photodynamic therapy of pre-cancerous skin lesions (actinic keratosis). The ALA nanoemulsion is applied to the skin lesions and, upon irradiation, a chemical reaction is triggered which destroys the affected skin without scar formation.
Actinic keratosis
Actinic keratosis or solar keratosis is a precancerous skin lesion. These lesions develop as single, small plaques on the face or bald scalp of a patient and then gradually progress in sun-exposed areas, such as the nose, the forehead, and the cheeks. About 10% of non-treated actinic keratosis progresses to invasive squamous cell carcinoma. Actinic keratosis is the 3rd most common reason for attending a dermatologist. The estimated incidence for actinic keratosis is 5 million new cases per year in Europe.
About Biofrontera AG
Biofrontera AG is specialized in the development of pharmaceutical products in the area of dermatology. The company is characterized by a broad, relatively close-to-the-market product portfolio and a solid liquidity. Biofrontera is listed in the regulated market of the Duesseldorf stock exchange and other German stock markets under the symbol B8F and the ISIN number DE0006046113. Visit the website at www.biofrontera.com.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
CEO and President
941-366-3400
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
SOURCE: DNAPrint Genomics, Inc.
Copyright 2006 Market Wire, All rights reserved.
-0-
DNAG FFLLYYYYYYYYYYYYYYIIIINNNNNNNNNGGGGGG
DNAG UP 40% and 8Mio Vol.
DNAG UPPPP 30%
LLLLLOLLLLLLLLLLL
DNAG RRRRUUNNNNNNINNNNNGGGGGG
DNAG RRRRUUUUUUUUUUNNNNNNNNNNNNNIIIIIINNNNNNNNNNNGGGGGGGG
DNAG Running
DNAPrint Announces Discovery of Genetic Marker for Statin-Induced Myalgia
Findings From Company's Statnome Project Successfully Validated; Article on Study to Be Published in Noted Academic Journal
SARASOTA, FL -- (MARKET WIRE) -- December 19, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG), today announced that the Company's research staff has discovered a genetic marker for statin-induced myalgia (chronic muscle pain), that a patent has been filed to protect the discovery and that the research on which the discovery is based will be published in an upcoming issue of The Journal of Pharmacogenetics and Genomics (JPG).
The marker was the primary discovery from the Company's Statnome project initiated in 2000 and the manuscript to be published in JPG describes the validation of this finding in different patient samples.
"Myalgia or chronic muscle pain is a common side effect reported by patients who take statins for cholesterol control, and it is likely to be part of a disease continuum that includes myositis and rhabdomyolysis, which is a breakdown of muscle fibers that frequently results in kidney damage and is a potentially fatal side-effect," according to DNAPrint Chief Science Officer Tony Frudakis, Ph.D. "Deaths associated with statin-induced rhabdoymyolysis lead Bayer to withdraw Cerivistatin in 2001. We are satisfied to have brought one of our first pharmacogenetics programs full circle from discovery through validation and we consider the R&D phase for this project complete. With the filing of a patent to protect this discovery, the Company will be able to develop a proprietary test for this gene variant and thereby reduce the likelihood of illness or death in those patients who are taking statins. This study also criticizes the original clinical trials for statins, which did not fully or adequately explore the relationship between statins and myalgia or even rhabdomyolysis."
"This is the culmination of a project that was begun when the company was founded," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It has taken until now to validate the original findings, but validated they are. The Company has filed a patent to protect this process. We plan to bring to market a definitive test product to identify this genetic variant and to potentially prevent painful -- and in some cases, fatal -- side effects in thousands of patients who are taking a very common prescription drug."
Highlighted Links
MacReport.Net
DNAPrint™ genomics, Inc.
DNAPrint's study of 750 patients who had taken either atorvastatin (Lipitor®) or simvastatin (Zocor®) showed that patients carrying one specific genetic marker were approximately 2.5 times more likely to experience mild to severe muscle pain (myalgia). The effect was most pronounced for atorvastatin and the study showed that approximately one half of the patients who were removed from atorvastatin therapy due to muscle symptoms possess this genetic marker, whereas in the general population (with and without cardiovascular disease) only approximately 15%-25% of people carry the marker. DNAPrint applied its technology for measuring population structure (e.g., ancestry) in order to prove that the finding in both the discovery and validation samples was genuine, and in so doing received praise from JPG reviewers. This observation indicates that the genetic marker may be related not only to response to statins but also to a possible relationship with higher cholesterol levels, according to the study.
"DNA Print Genomics was founded on the underlying genomic screening methods developed to more efficiently scan the genome for medically important genetic markers of drug responses," stated Dr. Frudakis. "The current findings are another example of the efficiency of the Company's methods."
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
DNAPrint Genomics Launches Personal, Confidential DNA Storage Service
New Offering Complements DNA Testing Products and Is Seen as Aiding Health Diagnostics and Investigations or as a Holiday Gift
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the launch of its personal DNA Storage Service, designed to complement the Company's comprehensive line of genetic ancestry products and to ensure the confidentiality of personal DNA data for future testing or personal use.
"We offer this service because everyone should establish genetic profiles for themselves and their children," stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. "The Company's line of DNA ancestry products, such as AncestryByDNA(TM) and EuroDNA(TM), can be used in this way and to explore family heritage at the same time. DNA testing may also be used to predict individual sensitivities or side effects to certain drugs. Moreover, with the current backlog of cases at various investigative agencies, we feel that establishing a sample file with DNAPrint could help speed up the process of finding anyone -- especially children -- who may go missing. For these reasons among many, we would certainly encourage individuals to have their DNA tested at the same time that it is stored."
The basic DNA storage plan is available at an initial cost of $39.00 and is renewed annually. The Company also offers fully paid storage at a discount for 5-year increments. An STRmap analysis service is also offered for those wanting their DNA to be typed at 16 genetic markers that may be used for human identity in addition to storage. The Company's AncestryByDNA(TM) and EuroDNA(TM) products are available separately and can be used to trace genetic heritage among the four anthropological groups: Native American; East Asian; Sub-Saharan African (areas south of the Sahara Desert); Indo-European (Europe, Middle East, North Africa, Western Asia).
"We also appreciate that this is the time of year when people are looking for unusual and unique gift ideas," Mr. Gabriel said. "This service, in conjunction with DNAPrint's complete line of genetic history products, would certainly qualify as a special gift, providing a great opportunity to share a new understanding of one's family tree and help strengthen the bonds between generations."
"DNA is very stable when stored under the proper conditions and DNAPrint is an expert in this area," said Anthony Frudakis, Ph.D., Chief Scientific Officer and founder of DNAPrint. "There have been many requests from the general public about storing DNA, so the Company has put together a retrieval and storage package that is painless and doesn't involve the use of blood. Storing DNA can be important to couples and families who may want to have their DNA evaluated and have the results reported back to them."
DNA is retrieved using the DNAPrint Genomics, Inc. non-invasive collection product, which in the past has been used to safely collect more than 26,000 samples. Samples are taken from cheek cells using a swab and instructions that come with each kit. The DNA is stored in a moisture-free environment with a quality assurance monitoring program. DNA storage under dry conditions is the key to long lasting DNA. Experts note that microbes, fungi and other organisms do not survive without moisture, so a dry, cool environment significantly lengthens the DNA storage life. Of course, the person submitting the sample retains ownership.
DNAPrint Genomics, Inc. is a premier testing laboratory offering the only autosomal test for Bio-Geographical Ancestry called AncestryByDNA(TM). The forensic version of this test, DNAWitness(TM) 2.5, has been used in over 150 cases to date. This experience in the forensic field, as well as work with ancient DNA samples, has developed a level of knowledge and skill that will benefit the DNA storage program. In addition to the AncestryByDNA(TM) and DNAWitness(TM) test, DNAPrint offers mitochondrial, Y-chromosome, and paternity testing. The DNA storage program and its upgrade will allow customers to take advantage of DNAPrint's present and future services and products as they become available. DNA storage assists families, couples and individuals in preserving their DNA as the age of DNA testing advances.
"DNA technology is advancing so rapidly that it's almost impossible to predict what the next ten to twenty years will hold," stated Mr. Gabriel. "Storing an individual's DNA may open up a world of options in specialized medicine for those that have preserved their DNA. When new tests come out, if the person is interested, we can screen their DNA rapidly and provide them with new information on their potential response to drugs or to the progression of disease. All of our services are compliant with HIPPA and we maintain the strictest confidentiality."
To order the new services, call customer service at 941-366-3400, extension 230.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Source: Market Wire (December 15, 2006 - 7:00 AM EST)
News by QuoteMedia
www.quotemedia.com
OK,also ein Dummschwaetzer
jever000,You Talk every Time the News comes Today????????????
I Think DNAG Hold 18% from Biofronrera?????
Handelsplatz
Symbol / Währung. Letzter
Umsatz +/-
% Zeit
Datum Bid
Ask Vortag
Erster Hoch
Tief Volumen
Umsatz
Xetra
B8F / EUR 15,30
20 -0,050
-0,33 10:02:22
13.12.2006 14,95
15,30 15,35
15,30 15,30
15,30 20
306
Stuttgart
B8F / EUR 14,81
0 +0,00
+0,00 09:15:07
13.12.2006 14,96
15,29 14,81
14,81 14,81
14,81 0
0
Düsseldorf
B8F / EUR 14,93
150 +0,070
+0,47 09:13:02
13.12.2006 14,95
15,30 14,86
14,93 14,93
14,93 0
0
Berlin
B8F / EUR 15,20
0 +0,00
+0,00 09:09:08
13.12.2006 -
15,20 15,20
15,20 15,20
15,20 0
0
Frankfurt
B8F / EUR 15,15
120 -0,0100
-0,07 09:07:40
13.12.2006 14,93
15,39 15,16
15,15 15,15
15,15 0
6.284
First human study with Biofrontera´s migraine prophylaxis product
Leser des Artikels: 42
Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
Leverkusen, Germany - Biofrontera AG today announced that the
responsible local Authority and the Ethical Committee have approved
the first study in humans of Biofrontera´s drug candidate BF-1.
Biofrontera develops BF-1 for the prophylactic treatment of severe
migraine. The clinical trial represents the first application of the
compound to human volunteers.
The trial is supervised by Xeleron Inc., York, England and will be
performed by Xendo Drug Development B.V. in the Netherlands. The goal
of the study is to assess the rate at which applied BF-1 enters the
blood stream, how long it will be present in the blood and to which
extent it will be degraded before elimination. Provided that the
enrollment of test persons will proceed as planned, Biofrontera
expects preliminary results by the end of the year.
BF-1 is the leading product of Biofrontera´s maturing preclinical
product portfolio of anti-inflammatory drugs which acts as a highly
selective and potent 5-HT2B receptor inhibitor.
"We believe that the medical need for the prophylaxis of migraine is
enormous. We expect BF-1 to be effective in migraine prophylaxis
without any relevant adverse side effects. Our hope is that this
initial clinical trial will provide information that is relevant for
the strategic planning of the further development," commented Dr.
Reinhold Gahlmann, Biofrontera´s Head of Drug Development.
Migraines are acute, periodically occurring attacks of very severe
headache, usually affecting only one side of the head and often
accompanied by nausea and vomiting. It is estimated that
approximately 10-12% of the population in industrialized countries
suffer from migraine attacks. Biofrontera believes that prophylactic
treatment is indicated for the 10-20% of the patients with frequent
attacks.
About Biofrontera AG
Biofrontera AG is specialized in the development of pharmaceutical
products in the area of dermatology. The company is characterized by
a broad, relatively close to the market product portfolio and a solid
liquidity. Biofrontera is listed in the regulated market of the
Düsseldorf stock exchange under the symbol B8F and the ISIN number
DE0006046113.
For further information please contact:
Anke zur Mühlen
Corporate Communication
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen@biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
The press release can be downloaded from the following link:
Nachricht vom 11.12.2006 | 12:46 10 mal gelesen
Rapid progress in Clinical Phase IIb/III trial for actinic keratosis
Leser des Artikels: 10
Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
Leverkusen, Germany - Biofrontera AG (Stock market symbol: B8F) today
announced that the enrolment of patients in the first part of its
phase IIb/III clinical trial with BF-200 ALA is completed.
The study evaluates the efficacy and safety of BF-200 ALA in the
treatment of actinic keratosis. Initially, clinical results for three
different doses of the active ingredient 5-aminolevulinic acid (ALA)
and placebo are compared. Following the treatment and 2-month
observation of 80 patients enrolled in the first part of the study,
independent experts will perform an interim analysis to select the
optimal dose of the drug. All 80 patients have already completed the
treatment and Biofrontera expects the results of the interim analysis
in the first quarter 2007. Subsequently, efficacy and safety of
BF-200 ALA will be verified with additional 160 patients.
The randomized, placebo-controlled clinical phase IIb/III trial is
conducted in 13 centers in Germany. In parallel to the ongoing trial,
a second phase III trial is currently prepared with approximately 200
patients to compare BF-200 ALA with a standard therapy. Excellent
clinical efficacy of combinations of ALA with nanoemulsions has
already been demonstrated for superficial basal cell carcinoma in two
earlier phase II trials, where a single treatment eliminated more
than 80 % of the tumors.
BF-200 ALA
Biofrontera´s lead product BF-200 ALA combines a nanoemulsion with
5-aminolevulinic acid (ALA). The product is developed for the
photodynamic therapy of pre-cancerous skin lesions (actinic
keratosis). The ALA nanoemulsion is applied to the skin lesions and,
upon irradiation, a chemical reaction is triggered which destroys the
affected skin without scar formation.
Actinic keratosis
Actinic keratosis or solar keratosis is a precancerous skin lesion.
These lesions develop as single, small plaques on the face or bald
scalp of a patient and then gradually progress in sun-exposed areas,
such as the nose, the forehead, and the cheeks. About 10% of
non-treated actinic keratosis progresses to invasive squamous cell
carcinoma.
Actinic keratosis is the 3rd most common reason for attending a
dermatologist. The estimated incidence for actinic keratosis is 5
million new cases per year in Europe.
About Biofrontera AG
Biofrontera AG is specialized in the development of pharmaceutical
products in the area of dermatology. The company is characterized by
a broad, relatively close to the market product portfolio and a solid
liquidity. Biofrontera is listed in the regulated market of the
Düsseldorf stock exchange and other German stock markets under the
symbol B8F and the ISIN number DE0006046113.
www.biofrontera.com
For further information please contact:
Anke zur Mühlen
Corporate Communication
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen@biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
The press release can be downloaded from the following link:
--- End of Message ---
WKN: 604611; ISIN: DE0006046113;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse;
Copyright © Hugin ASA . All rights reserved.
Wertpapiere des Artikels:
DE0006046113
--------------------------------------------------------------------------------
Autor: Hugin
© Hugin ASA. All rights reserved.
SORRY 84lol
DNAG -- DNAPrint Genomics, Inc.
Com ($0.001)(New)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
OTCPicks.com: Otcpicks.com Daily Market Movers Digest Stock Alerts Monday, December 11th, DNAG
Dec 11, 2006 (M2 PRESSWIRE via COMTEX) -- Today our stock watch alerts today include stock alerts for DNAPrint Genomics, Inc. (OTCBB: DNAG), ViewCast.com, Inc. (OTCBB: VCST), International Monetary Systems, Ltd. (OTCBB: INLM) Water Chef, Inc. (OTCBB: WTER), and HemoBioTech, Inc. (OTCBB: HMBT)
Visit http://www.otcpicks.com to register for our FREE Daily Market Mover's Digest Newsletter and Stock Alerts
OTC STOCK ALERT
DNAPRINT GENOMICS, INC. (OTCBB: DNAG) "Up 41.43% at close on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/DNAG.php
DNAPrint Genomics, Inc. (OTCBB: DNAG) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests.
News:
December 8 - DNAPrint Pharmaceuticals / Harvard Study Shows PT-401 to Be Three Times More Potent Than Conventional EPOs in Treating Anemia
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the results of preclinical studies conducted by the Company and Harvard Medical School on the Company's proprietary PT-401 protein. The studies demonstrate that PT-401 is three times more effective than conventional EPO treatments, and conclude that PT-401 has "biological activities superior to those of EPO monomer, suggesting important therapeutic advantages."
The results of the study will be formally presented by Drs. Jee-Yeong Jeong and Arthur J. Sytkowski on Dec. 9, 2006, at the American Society of Hematology 48th Annual Meeting and Exposition in Orlando, Fla. Dr. Sytkowski is the Director of the Laboratory for Cell and Molecular Biology at Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Harvard Medical School.
The study's purpose was to determine whether it was possible to develop a more effective erythropoiesis stimulating agent (ESA) than human erythropoietin (EPO, epoetin), which is widely used in the treatment of certain forms of anemia but which has a relatively short in vivo half-life, resulting in considerably high and frequent doses in order to maintain therapeutic effectiveness. The study, conducted over a seven day period using laboratory mice, showed that the "super EPO" that forms the basis for PT-401, and which comprises EPO-dimer and EPO-trimer fusion proteins that were comprised of "head-to-tail" repeats, is up to three times more effective than conventional EPO treatments, exhibiting enhanced biological properties in vitro and in vivo.
"Dr. Sytkowski is one of the foremost scientists in the field of therapeutic protein research, particularly Erythropoietin," stated DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "We are proud that our affiliation with Dr. Sytkowski and Beth Israel Deaconess Medical Center has produced this research, which shows the promise of PT-401 in treating chronic anemia due to renal failure, cancer, or other causes."
"This study is an important step in the advancement of PT-401 as a potential competitor in the EPO market, which currently exceeds $10 billion and is rapidly growing," stated DNAPrint Genomics President and Chief Executive Officer Richard J. Gabriel. "This study is just one step, however, and we look forward to continuing our collaboration with Dr. Sytkowski as this project advances."
PT-401 is a "Super EPO," a more powerful erythropoiesis stimulating agent than Erythropoietin, a well-known drug used for the treatment of anemia. Previously, DNAPrint Pharmaceuticals, the Company's wholly owned subsidiary, announced three successful milestones related to PT-401: the use of CHO cell lines, the use of SDS-PAGE, a well-established separation technique for the testing of cell lines, and a specially developed isoelectric focusing (IEF) method. The initial research has been conducted in conjunction with Dr. Sytkowski.
In addition to Dr. Sytkowski, research was carried out with Drs. Jee-Yeong Jeong, Changmin Chen and Kerry L. Davis of the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at the Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School.
The study was conducted in conjunction with the UCLA Olympic Analytical Laboratory in the Department of Molecular and Medical Pharmacology at the University of California at Los Angeles and included Drs. Andreas Breidbach and Don H. Caitin.
The study and its results are illustrated in a multi-color poster that Dr. Sytkowski will distribute as part of the presentation.
I Think this is the HIGHFLYER
biofrontera M/K 50 Mio€ 18% Hold DNAG
DNAG 4,2 Mio Lol
DNAG Good News from Germany
Biofrontera: Rapid progress in Clinical Phase IIb/III trial for actinic keratosis
http://www.biofrontera.com/cms/index.php?id=51&L=1
Latest News
11 December 2006
Rapid progress in Clinical Phase IIb/III trial for actinic keratosis
PDF-File
20 November 2006
First human study with Biofrontera's migraine prophylaxis product
PDF-File
30 Oktober 2006
Biofrontera AG announces Listing
PDF-File
DNAG UP to 66,25% in Germany this Morning
Frankfurt 0,013 +62,50% 09:25 11.12.
DNAG UP to 66,25% in Germany this Morning
Frankfurt 0,013 +62,50% 09:25 11.12.
Germany UP 66,25% in Morning
Frankfurt 0,013 +62,50% 09:25 11.12.
DNAG NEXT BAGGER
2006-12-08 07:00 ET - News Release
SARASOTA, FL -- (MARKET WIRE) -- 12/08/06
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the results of preclinical studies conducted by the Company and Harvard Medical School on the Company\'s proprietary PT-401 protein. The studies demonstrate that PT-401 is three times more effective than conventional EPO treatments, and conclude that PT-401 has "biological activities superior to those of EPO monomer, suggesting important therapeutic advantages."
The results of the study will be formally presented by Drs. Jee-Yeong Jeong and Arthur J. Sytkowski on Dec. 9, 2006, at the American Society of Hematology 48th Annual Meeting and Exposition in Orlando, Fla. Dr. Sytkowski is the Director of the Laboratory for Cell and Molecular Biology at Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Harvard Medical School.
The study\'s purpose was to determine whether it was possible to develop a more effective erythropoiesis stimulating agent (ESA) than human erythropoietin (EPO, epoetin), which is widely used in the treatment of certain forms of anemia but which has a relatively short in vivo half-life, resulting in considerably high and frequent doses in order to maintain therapeutic effectiveness. The study, conducted over a seven day period using laboratory mice, showed that the "super EPO" that forms the basis for PT-401, and which comprises EPO-dimer and EPO-trimer fusion proteins that were comprised of "head-to-tail" repeats, is up to three times more effective than conventional EPO treatments, exhibiting enhanced biological properties in vitro and in vivo.
"Dr. Sytkowski is one of the foremost scientists in the field of therapeutic protein research, particularly Erythropoietin," stated DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "We are proud that our affiliation with Dr. Sytkowski and Beth Israel Deaconess Medical Center has produced this research, which shows the promise of PT-401 in treating chronic anemia due to renal failure, cancer, or other causes."
"This study is an important step in the advancement of PT-401 as a potential competitor in the EPO market, which currently exceeds $10 billion and is rapidly growing," stated DNAPrint Genomics President and Chief Executive Officer Richard J. Gabriel. "This study is just one step, however, and we look forward to continuing our collaboration with Dr. Sytkowski as this project advances."
PT-401 is a "Super EPO," a more powerful erythropoiesis stimulating agent than Erythropoietin, a well-known drug used for the treatment of anemia. Previously, DNAPrint Pharmaceuticals, the Company\'s wholly owned subsidiary, announced three successful milestones related to PT-401: the use of CHO cell lines, the use of SDS-PAGE, a well-established separation technique for the testing of cell lines, and a specially developed isoelectric focusing (IEF) method. The initial research has been conducted in conjunction with Dr. Sytkowski.
In addition to Dr. Sytkowski, research was carried out with Drs. Jee-Yeong Jeong, Changmin Chen and Kerry L. Davis of the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at the Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School.
The study was conducted in conjunction with the UCLA Olympic Analytical Laboratory in the Department of Molecular and Medical Pharmacology at the University of California at Los Angeles and included Drs. Andreas Breidbach and Don H. Caitin.
The study and its results are illustrated in a multi-color poster that Dr. Sytkowski will distribute as part of the presentation.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company\'s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company\'s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company\'s drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint\'s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint\'s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
DNAG Next xxxBagger
DNAG -- DNAPrint Genomics, Inc.
Com ($0.001)(New)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
DNAPrint Pharmaceuticals / Harvard Study Shows PT-401 to Be Three Times More Potent Than Conventional EPOs in Treating Anemia
"Important Therapeutic Advantages" Are Suggested; Results to Be Released at American Society of Hematology Annual Meeting
SARASOTA, FL, Dec 08, 2006 (MARKET WIRE via COMTEX) -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the results of preclinical studies conducted by the Company and Harvard Medical School on the Company's proprietary PT-401 protein. The studies demonstrate that PT-401 is three times more effective than conventional EPO treatments, and conclude that PT-401 has "biological activities superior to those of EPO monomer, suggesting important therapeutic advantages."
The results of the study will be formally presented by Drs. Jee-Yeong Jeong and Arthur J. Sytkowski on Dec. 9, 2006, at the American Society of Hematology 48th Annual Meeting and Exposition in Orlando, Fla. Dr. Sytkowski is the Director of the Laboratory for Cell and Molecular Biology at Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Harvard Medical School.
The study's purpose was to determine whether it was possible to develop a more effective erythropoiesis stimulating agent (ESA) than human erythropoietin (EPO, epoetin), which is widely used in the treatment of certain forms of anemia but which has a relatively short in vivo half-life, resulting in considerably high and frequent doses in order to maintain therapeutic effectiveness. The study, conducted over a seven day period using laboratory mice, showed that the "super EPO" that forms the basis for PT-401, and which comprises EPO-dimer and EPO-trimer fusion proteins that were comprised of "head-to-tail" repeats, is up to three times more effective than conventional EPO treatments, exhibiting enhanced biological properties in vitro and in vivo.
"Dr. Sytkowski is one of the foremost scientists in the field of therapeutic protein research, particularly Erythropoietin," stated DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "We are proud that our affiliation with Dr. Sytkowski and Beth Israel Deaconess Medical Center has produced this research, which shows the promise of PT-401 in treating chronic anemia due to renal failure, cancer, or other causes."
"This study is an important step in the advancement of PT-401 as a potential competitor in the EPO market, which currently exceeds $10 billion and is rapidly growing," stated DNAPrint Genomics President and Chief Executive Officer Richard J. Gabriel. "This study is just one step, however, and we look forward to continuing our collaboration with Dr. Sytkowski as this project advances."
PT-401 is a "Super EPO," a more powerful erythropoiesis stimulating agent than Erythropoietin, a well-known drug used for the treatment of anemia. Previously, DNAPrint Pharmaceuticals, the Company's wholly owned subsidiary, announced three successful milestones related to PT-401: the use of CHO cell lines, the use of SDS-PAGE, a well-established separation technique for the testing of cell lines, and a specially developed isoelectric focusing (IEF) method. The initial research has been conducted in conjunction with Dr. Sytkowski.
In addition to Dr. Sytkowski, research was carried out with Drs. Jee-Yeong Jeong, Changmin Chen and Kerry L. Davis of the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at the Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School.
The study was conducted in conjunction with the UCLA Olympic Analytical Laboratory in the Department of Molecular and Medical Pharmacology at the University of California at Los Angeles and included Drs. Andreas Breidbach and Don H. Caitin.
The study and its results are illustrated in a multi-color poster that Dr. Sytkowski will distribute as part of the presentation.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
SOURCE: DNAPrint Genomics, Inc.
Copyright 2006 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Trials
Search for Dun & Bradstreet reports on this company
DNAG Next xxxBagger
DNAG -- DNAPrint Genomics, Inc.
Com ($0.001)(New)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
DNAPrint Pharmaceuticals / Harvard Study Shows PT-401 to Be Three Times More Potent Than Conventional EPOs in Treating Anemia
"Important Therapeutic Advantages" Are Suggested; Results to Be Released at American Society of Hematology Annual Meeting
SARASOTA, FL, Dec 08, 2006 (MARKET WIRE via COMTEX) -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the results of preclinical studies conducted by the Company and Harvard Medical School on the Company's proprietary PT-401 protein. The studies demonstrate that PT-401 is three times more effective than conventional EPO treatments, and conclude that PT-401 has "biological activities superior to those of EPO monomer, suggesting important therapeutic advantages."
The results of the study will be formally presented by Drs. Jee-Yeong Jeong and Arthur J. Sytkowski on Dec. 9, 2006, at the American Society of Hematology 48th Annual Meeting and Exposition in Orlando, Fla. Dr. Sytkowski is the Director of the Laboratory for Cell and Molecular Biology at Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Harvard Medical School.
The study's purpose was to determine whether it was possible to develop a more effective erythropoiesis stimulating agent (ESA) than human erythropoietin (EPO, epoetin), which is widely used in the treatment of certain forms of anemia but which has a relatively short in vivo half-life, resulting in considerably high and frequent doses in order to maintain therapeutic effectiveness. The study, conducted over a seven day period using laboratory mice, showed that the "super EPO" that forms the basis for PT-401, and which comprises EPO-dimer and EPO-trimer fusion proteins that were comprised of "head-to-tail" repeats, is up to three times more effective than conventional EPO treatments, exhibiting enhanced biological properties in vitro and in vivo.
"Dr. Sytkowski is one of the foremost scientists in the field of therapeutic protein research, particularly Erythropoietin," stated DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "We are proud that our affiliation with Dr. Sytkowski and Beth Israel Deaconess Medical Center has produced this research, which shows the promise of PT-401 in treating chronic anemia due to renal failure, cancer, or other causes."
"This study is an important step in the advancement of PT-401 as a potential competitor in the EPO market, which currently exceeds $10 billion and is rapidly growing," stated DNAPrint Genomics President and Chief Executive Officer Richard J. Gabriel. "This study is just one step, however, and we look forward to continuing our collaboration with Dr. Sytkowski as this project advances."
PT-401 is a "Super EPO," a more powerful erythropoiesis stimulating agent than Erythropoietin, a well-known drug used for the treatment of anemia. Previously, DNAPrint Pharmaceuticals, the Company's wholly owned subsidiary, announced three successful milestones related to PT-401: the use of CHO cell lines, the use of SDS-PAGE, a well-established separation technique for the testing of cell lines, and a specially developed isoelectric focusing (IEF) method. The initial research has been conducted in conjunction with Dr. Sytkowski.
In addition to Dr. Sytkowski, research was carried out with Drs. Jee-Yeong Jeong, Changmin Chen and Kerry L. Davis of the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at the Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School.
The study was conducted in conjunction with the UCLA Olympic Analytical Laboratory in the Department of Molecular and Medical Pharmacology at the University of California at Los Angeles and included Drs. Andreas Breidbach and Don H. Caitin.
The study and its results are illustrated in a multi-color poster that Dr. Sytkowski will distribute as part of the presentation.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
SOURCE: DNAPrint Genomics, Inc.
Copyright 2006 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Trials
Search for Dun & Bradstreet reports on this company.
Shakerzzz,you are out by PHEI ???????
Some Question!!!!!!!!
But even we Closed over 0,008
SHORTIE
Fresh Trader1000 Oute Dich mal WO-Board
http://www.wallstreet-online.de/informer/community/thread.html?thread_id=1093369&inst_id=186527&...
November 29, 2006 - 9:00 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
ASWD 1.51 0.00
Today 5d 1m 3m 1y 5y 10y
American Southwest Music Distribution announces marketing strategy
LAS VEGAS, NV, Nov. 29 /CNW/ - American Southwest Music Distribution,
Inc. (OTC: ASWD.OB) announces marketing strategy.
In August 2006, American Southwest Music Distribution began marketing
music to consumers worldwide. Universal Records, a division of UMG Recordings,
Inc. (the world's largest distributor of consumer entertainment products) is
the exclusive worldwide manufacturer and distributor of American Southwest
Music's consumer entertainment products.
Although the company will focus on selling music and motion pictures
previously not released to consumers, they own a music catalog consisting of
rights to master recordings acquired from two other record labels: Celestial
Breakaway and Out of Control Records. Celestial Breakaway and Out of Control
previously released these master recordings to consumers, and American
Southwest Music plans to re-release these masters to consumers through retail
and digital distribution. Because of their previous commercial success,
American Southwest Music's management expects that these masters will generate
steady revenues for the company.
A substantial part of American Southwest Music's activity will be devoted
to the acquisition of worldwide rights to new master recordings from recording
artists and record production companies, and the acquisition of new motion
pictures produced by production companies seeking worldwide distribution for
their works.
American Southwest Music's rights to new master recordings will be
embodied in record contracts with recording artists and production companies.
In each record contract, American Southwest Music acquires the exclusive
worldwide copyright and right to manufacture, distribute and license products
derived from the new master recordings created by those recording artists.
Through distribution contracts, American Southwest Music will obtain the
exclusive worldwide right to manufacture and distribute to consumers for home
entertainment use, through retail and digital formats, motion pictures
produced by third-party film production companies. American does not plan to
be involved in the production of any motion picture or the theatrical release
of any motion picture.
American Southwest Music Distribution, Inc. (www.ASWMD.com) is a publicly
held company that has partnered with Universal Music Group to begin marketing
and selling music and motion pictures to consumers worldwide.
Cautionary Statement:
This news release may contain certain forward-looking statements within
the meaning of Section 27A of the Securities and Exchange Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, which are intended to be covered by the safe harbors created thereby.
Investors are cautioned that all forward-looking statements involve risks and
uncertainties. Although American Southwest Music Distribution, Inc. believes
that the assumptions underlying the forward-looking statements contained
herein are reasonable, any assumption could be inaccurate, and therefore,
there can be no assurance that the forward-looking statements included herein,
the inclusion should not be regarded as a representation by American Southwest
Music Distribution, Inc., or any other person that the objectives and plans of
American Southwest Music Distribution, Inc. will be achieved.
Source: Canada NewsWire (November 29, 2006 - 9:00 AM EST)
News by QuoteMedia
www.quotemedia.com
PTSH -- PTS, Inc.
Com ($0.001)(New)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
PTS, Inc. Establishes Stock Dividend Ratio for Disability Access Corporation at 1:3
LAS VEGAS, Nov 20, 2006 (BUSINESS WIRE) -- The Board of Directors of PTS, Inc. (OTCBB:PTSH) announced today that they have established the ratio of the pending stock dividend of Disability Access Corporation (Pink Sheets:DBAC) at a ratio of 1:3. This means that for every three (3) shares of PTS, Inc. owned at record date, one (1) share of Disability Access Corporation post split stock will be paid. The date the DBAC-Pink Sheets forward split, as previously announced, will be effective on 11-30-2006.
The date of record for the PTS, Inc. shareholders entitled to receive this dividend distribution will be at the close of business Friday, December 15, 2006.
About Disability Access Corporation
Disability Access Corporation (DBAC-Pink Sheets) conducts facility inspections, policy reviews and program analyses in addition to a comprehensive continuum of other compliance services. More than 54 million people in the United States have a disability, a number equal to 20% of the population. The Americans with Disabilities Act of 1990 requires all organizational entities, public or private, with more than 15 employees, to provide equal access for individuals with disabilities. It is estimated that there are more than seven million sites at risk across the United States. For more information about DAC, please visit: www.adaconsultants.com.
About PTS, Inc.
PTS, Inc.'s subsidiary, Glove Box Inc. (www.ptspi.com), owns the rights to the patented, revolutionary Glove Box(TM), the only product that offers contamination reduction through automated glove dispensing. The Glove Box(TM) system is a free-standing dispenser of disposable latex gloves, which is being marketed by PTS in the United States and Asia.
Safe Harbor Statement Regarding Forward-Looking Statements:
Except for historical information contained herein, the statements in this news release are forward-looking statements that involve risks and uncertainties and are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the company's actual results in the future periods to differ materially from forecasted results.
SOURCE: Disability Access Corporation
CONTACT: PTS, Inc.
Peter Chin, 702-327-7266
psc3388@yahoo.com
Copyright Business Wire 2006
-0-
KEYWORD: United States
North America
Nevada
INDUSTRY KEYWORD: Health
Medical Devices
Other Health
Professional Services
Human Resources
SUBJECT CODE: Dividend
Search for Dun & Bradstreet reports on this company.
Frankfurt
WMU / EUR 0,077
12.000 +0,032
+71,11 11:12:34
20.11.2006 0
bid 0,050
ask 0,100
Berlin
PJ3B / EUR 0,0090
470.700 +0,0020
+28,57 18:44:53
16.11.2006 0,0090
0,0100 0,0070
0,0070 0,0100
0,0070 13.877.646
124.899
Frankfurt
PJ3B / EUR 0,0090
57.000 +0,0010
+12,50 17:43:22
16.11.2006 0,0080
0,0090 0,0080
0,0070 0,0100
0,0070 1.539.000
13.406